Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Short term Debt (2016 - 2025)

Historic Short term Debt for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $9.1 million.

  • Aytu Biopharma's Short term Debt rose 12619.64% to $9.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.1 million, marking a year-over-year increase of 12619.64%. This contributed to the annual value of $9.1 million for FY2025, which is 27841.34% up from last year.
  • According to the latest figures from Q4 2025, Aytu Biopharma's Short term Debt is $9.1 million, which was up 12619.64% from $14.9 million recorded in Q3 2025.
  • Aytu Biopharma's 5-year Short term Debt high stood at $16.7 million for Q2 2021, and its period low was $1.0 million during Q4 2023.
  • In the last 5 years, Aytu Biopharma's Short term Debt had a median value of $7.8 million in 2022 and averaged $8.0 million.
  • Its Short term Debt has fluctuated over the past 5 years, first skyrocketed by 159735.23% in 2021, then crashed by 8618.93% in 2023.
  • Over the past 5 years, Aytu Biopharma's Short term Debt (Quarter) stood at $16.3 million in 2021, then plummeted by 54.54% to $7.4 million in 2022, then tumbled by 86.19% to $1.0 million in 2023, then skyrocketed by 291.03% to $4.0 million in 2024, then soared by 126.2% to $9.1 million in 2025.
  • Its Short term Debt stands at $9.1 million for Q4 2025, versus $14.9 million for Q3 2025 and $9.1 million for Q2 2025.